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Abstract
Background: Surfactant metabolism disorders may result in diffuse lung disease in children.
Case presentation: We report a 3-years-old boy with dry cough, progressive hypoxemia, dyspnea and bilateral
ground glass opacities at chest high-resolution computed tomography (HRCT) who had no variants in genes
encoding surfactant proteins or transcription factors. Lung histology strongly suggested an abnormality of surfactant
protein. A 7-month course of pulse intravenous high-dose methylprednisolone plus oral hydroxychloroquine and
azithromycin led to gradual weaning from oxygen and oral steroids, and to improvement of cough and dyspnea. Over
the follow-up period, hydroxychloroquine and azithromycin were not withdrawn as cough and dyspnea re-appeared
at each attempt and disappeared at re-start. At 6 years of age chest HRCT still appeared unchanged, but clinical
symptoms or signs were absent.
Conclusions: In children suspected of inborn errors of pulmonary surfactant metabolism who do not have a recognized
genetic mutation, lung biopsy with consistent histology may help physicians to address the definitive diagnosis.
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Background
Pediatric diffuse lung disease (DLD) is a heterogeneous
group of uncommon disorders with impaired gas
exchange and diffuse infiltrates at chest imaging [1].
Deletions of or mutations in genes encoding proteins
important in surfactant production and function (SP-B,
SP-C, and ABCA3), surfactant catabolism (GM-CSF
receptor), or transcription factors important for surfactant
production (TTF1) or lung development (Fox F1) may
cause pediatric DLD [2]. The prognosis of surfactant
disorders is heterogeneous, with high mortality in SP-B
deficiency and variable severity in cases with mutations in
ABCA3 or SP-C [1, 3, 4]. Mutations of surfactant protein
genes are detected in most patients [2]. However, 20–30 %
of cases with histological pattern compatible with surfac-
tant disorders have no identified mutation [1].
We report a young child in whom lung histology
strongly suggested a surfactant disorder, but no variants
conclusively classified as pathogenic in genes encoding
surfactant proteins or transcription factors important for
surfactant production were found.
Case presentation
The child was a full-term male, born to unrelated par-
ents. There was no family history of lung disease. At
birth he required no resuscitation. By age 3 years he
developed fever with dry cough and dyspnea. Chest X-
ray showed mild-to-moderate interstitial thickening, and
IgM for Mycoplasma pneumoniae was detected. After
21 days of clarithromycin, fever disappeared. Respiratory
symptoms persisted unchanged also after two-month
course of inhaled steroids and montelukast. By age
3.6 years he was admitted to our hospital with persistent
dry cough and dyspnea, and progressive hypoxemia. On
examination, he had fine crackles and expiratory
wheezes bilaterally. Transcutaneous oxygen saturation
(SpO2) was 90 % at room air, but rose to 98 % at 4 liters/
minute oxygen delivered by nasal cannula. The remain-
der examination also including neurologic assessment
was normal. He could not perform spirometry.
Structural cardiovascular abnormalities were excluded
at echocardiography. Serological investigations ruled
out C. pneumoniae, adenovirus, metapneumovirus,
* Correspondence: santamar@unina.it
1Department of Translational Medical Sciences, Federico II University, Via
Sergio Pansini, 5 – 80131 Naples, Italy
Full list of author information is available at the end of the article
ITALIAN JOURNAL
OF PEDIATRICS
© 2015 Montella et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Montella et al. Italian Journal of Pediatrics  (2015) 41:93 
DOI 10.1186/s13052-015-0198-3
cytomegalovirus, and respiratory syncytial, influenza,
parainfluenza, Epstein-Barr, and human immunodefi-
ciency viruses. Airways anomalies were not evident at
flexible bronchoscopy. We did not perform bronchoal-
veolar lavage because it has limited value in identifying
the specific DLD or guiding therapy [1]. A 24 h pH-
impedance monitoring was normal. The sweat test was
negative and the genetic testing did not identify any
causative mutation of cystic fibrosis. Ultrastructural
analysis of nasal cilia was normal. Primary immune
defects were ruled out and serological testing for con-
nective tissue disorders were negative. Thyroid function
was normal. Chest high-resolution computed tomog-
raphy (HRCT) revealed multiple bilateral ground glass
opacities (Fig. 1a and b). A direct sequencing protocol
was applied to the coding regions and exon/intron
junctions of SFTPB, SFTPC, ABCA3, NKX2.1, and
NKX2.5 genes. Promoter and regulatory regions were
not analyzed because at present no mutation has been
described in these sites. Molecular analysis in these
genes did not reveal a pathogenic variant in the patient.
However, the IVS4+39 C>T heterozygous rare variant
(rs79253830) was identified in SFTPC by Sanger direct
sequencing. The child was also heterozygous for the
known ABCA3 single nucleotide polymorphisms
rs170447, rs313908, and rs149532.
A thoracoscopic lung biopsy was performed. Histology
showed widened alveoli with thickened alveolar septa
infiltrated mainly by fibroblasts and lymphocytes, hyper-
plasia of type-II pneumocytes, and intra-alveolar accumu-
lation of finely granular periodic acid Schiff-positive
material and several cholesterol crystals, suggesting pul-
monary alveolar proteinosis and nonspecific interstitial
pneumonia. At electron microscopy, alveolar type II cells
lacked mature cytoplasmic lamellar bodies, while other
organelles appeared normal, which was consistent with
surfactant protein abnormality. In particular, type II cell
cytoplasm showed numerous small structures containing
irregular and poorly staining material (Fig. 2).
Pulse intravenous high-dose methylprednisolone (30 mg/
kg once daily for three successive days each month), oral
hydroxychloroquine (10 mg/kg once daily) and azi-
thromycin (10 mg/kg once daily for three consecutive
days/week) were started. Prior to treatment, the pa-
tient underwent a six minute walking test that showed
a walk distance of 381 (72 % predicted) meters and a
minimum SpO2 during the walk of 81 %. Moreover, he
spent 89.4 % of the walk time with SpO2 <90 %. The
combined therapy led to gradual weaning from oxygen
and improvement of cough and dyspnea over seven
months. Oxygen and steroids were gradually with-
drawn, but oral hydroxychloroquine and azithromycin
continued. Six months after steroids and oxygen were
stopped, a substantial improvement of exercise toler-
ance versus pre-treatment test was observed as walk
distance was 441 meters (83 % predicted), with
Fig. 1 Baseline high-resolution computed tomography scans. Sharply defined areas of ground glass opacity more marked in the left upper
lobe (a), in the middle lobe, lingula and right lower lobe (b). High-resolution computed tomography at the age of 6 years (after 3 years of oral
hydroxychloroquine and azithromycin) showing unmodified ground glass attenuation in the same areas, indicating lung damage stabilization
(c and d)
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minimum SpO2 during the walk of 85 % and 45.5 % of
the walk time spent with SpO2 <90 %.
Over the follow-up, we tried to withdraw hydroxy-
chloroquine and azithromycin, but cough and dyspnea
re-appeared at each attempt, and rapidly disappeared at
re-start. Currently, the subject is 6 years-old, adherence
to treatment is satisfactory, with no side effects. Re-
peated daily SpO2 showed values not lower than 98 % at
room air, with median overnight values of 96 % (min
74 %, max 99 %). He is still unable to perform spirom-
etry. Chest HRCT is unchanged (Fig. 1c and d).
Discussion
In this child with no mutations in genes important for sur-
factant function and metabolism, lung biopsy suggested
surfactant dysfunction, but with some unusual features
including the absence of lamellar bodies. The significance
of this finding is unclear. However, considering the normal
ultrastructure of other cellular and nuclear membranes, it
is thought to be a real finding, unrelated to biopsy pro-
cessing or handling. Given the patient’s phenotype, this
pattern is consistent with a disorder of surfactant
metabolism.
For infants or young children with clinical, imaging,
and/or histological features suggestive of DLD, testing
for genetic abnormalities associated with surfactant dys-
function and/or NKX2.1 is recommended [2]. Although
positive results may obviate the need for lung biopsy,
individuals with unresolved disease in whom mutations
are not found require tissue sampling for achieving a
definitive diagnosis and guiding further diagnostic and
therapeutic choices [1].
Indeed, the recent scheme for pediatric DLD includes
conditions with histology consistent with surfactant dys-
function disorder without a yet recognized genetic muta-
tion [1, 5]. Actually, the sensitivity of genetic testing for
surfactant dysfunction disorders was not formally evalu-
ated and, although the frequency of false-negative results
cannot be precisely estimated, it has been assumed to be
low [1]. In particular, current analytical methods cannot
detect all mutations that cause surfactant disorders (i.e.,
large rearrangements identified by conventional Sanger
sequencing). Moreover, functionally significant variants
may be present in untranslated regions that are not
examined through routine clinical sequencing or in
other genes not yet associated to the disease [6]. In our
case, standard sequencing methodologies did not detect
mutations in SFTPB, ABCA3, and NKX2 genes, but only
identified the SFTPC IVS4 + 39C > T rare variant located
21 nucleotides downstream to the termination codon, in
the 3′UTR. Unfortunately, we could not perform RNA
analysis of the lung tissue and, although in silico algo-
rithms did not predict an effect on RNA splicing, we
cannot definitely exclude a possible pathogenic role of
the IVS4+39 C>T variant. Furthermore, we cannot
exclude the presence of a second unidentified mutation
on the other allele.
As the child was heterozygous for known ABCA3 sin-
gle nucleotide polymorphisms, homozygosity by descent
for the same rare ABCA3 allele is improbable. Thus, var-
iants in untranslated regions of or deletions in ABCA3
unlikely explain the child’s illness, as such variants are a
small minority of reported disease-causing ABCA3
alleles and would have to be present on two different
ABCA3 alleles. Finally, given the complexity of surfac-
tant synthesis, secretion, and catabolism, there are likely
to be as yet unidentified disorders of other molecules in
this pathway that, when mutated, result in a similar
histological phenotype.
Treatment of SP-C and ABCA3 abnormalities derives
from anecdotal experience. The variable clinical course
of pulmonary disease, combined with the lack of pro-
spective randomized controlled trials, makes it difficult
to uniform treatment strategies [2]. Treatment is based
on the concept that suppressing inflammation is sup-
posed to prevent the progression to pulmonary fibrosis.
Among the anti-inflammatory agents, steroids are the
preferred choice. As glucocorticoids increase ABCA3
expression in vitro [7], there is a rationale for intraven-
ous pulse steroids use in ABCA3 deficiency. Given the
limited evidence of a beneficial effect on clinical out-
comes and the well known side effects of immunosup-
pressive medications, whether or not to initiate a trial of
immunosuppressive therapy must be decided on an indi-
vidual basis. If steroids are given, patients should be
closely monitored for side effects, including periodic
measurement of weight and height, glucose homeostasis,
bone density, and ophthalmologic screening. Hydroxy-
chloroquine, an anti-malarial drug supposed to have
immunological effects [8], has also been often used for
Fig. 2 Type II pneumocyte cytoplasm. Numerous small structures
containing irregular and poorly staining material at electron microscopy
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treating DLD in children. If this drug is administered,
eye exams must be routinely performed to look for ret-
inal toxicity, although this complication is extremely rare
in children. Likewise, azithromycin has been used for its
anti inflammatory effects [1, 9]. As surfactant disorders
are incurable, supportive care is important for maintaining
optimal health status. This includes oxygen administration,
if required, and adequate nutritional support as well as
interventions to prevent infections such as pneumococcal
vaccine, annual influenza vaccination and routine child-
hood immunizations. Lung transplantation is an ultimate
option if progressive clinical deterioration unresponsive to
medical therapy develops [3, 4, 9]. In the current case, the
combined treatment of pulse methylprednisolone and
hydroxychloroquine plus azithromycin resulted in progres-
sive clinical resolution and lung damage stabilization.
Finally, a close follow-up is crucial to monitor the progres-
sion of disease.
Conclusions
Our report confirms that in children with suspected surfac-
tant dysfunction, genetic testing is strongly recommended
because it can provide a definitive diagnosis, may obviate
unnecessary procedures and interventions, and potentially
provide important prognostic information for families and
physicians [1]. Nevertheless, physicians should be aware of
the possibility of lung histology consistent with surfactant
disorder without a yet recognized genetic mutation.
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